Valuation: Supergenics

Market Cap 2.91Cr 71.47L 64.41L 59.51L 53.8L 1.02Cr 67Cr 1.04Cr 7.13Cr 2.84Cr 36Cr 2.68Cr 2.63Cr 114.24Cr P/E 2024
-9.45x
P/E 2025 -8.61x
Enterprise Value 3.25Cr 79.8L 71.92L 66.45L 60.07L 1.14Cr 75Cr 1.16Cr 7.96Cr 3.17Cr 40Cr 2.99Cr 2.93Cr 127.56Cr EV / Sales 2024
13.9x
EV / Sales 2025 5.78x
Free-Float
41.6%
Yield 2024 *
-
Yield 2025 -
1 year 0.25
Extreme 0.25
0.25
3 years 0.15
Extreme 0.15
0.6
5 years 0.15
Extreme 0.15
0.6
10 years 0.15
Extreme 0.15
0.6
Manager TitleAgeSince
Chief Executive Officer 48 24/04/2019
Corporate Secretary - 02/06/2022
Director TitleAgeSince
Director/Board Member 48 24/04/2019
Director/Board Member 60 24/04/2019
Director/Board Member 46 28/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
+21.95%-.--%+21.95%+8.70% 71.47L
+1.10%+1.03%+62.53%+70.47% 6.75TCr
+1.53%+8.95%+14.22%+93.13% 6.07TCr
+0.50%-0.95%+20.09%+98.45% 5.57TCr
+0.15%+8.46%+11.27%+111.21% 4.8TCr
-1.38%+1.86%+22.15%+39.31% 4.52TCr
-1.51%-0.08%+169.65%+803.36% 3.91TCr
+1.21%+4.75%+27.30%+52.81% 3.53TCr
-0.87%-2.89%+79.60%+56.33% 3.35TCr
-1.31%+9.53%-38.72%+398.41% 2.65TCr
Average +2.12%+2.43%+39.00%+173.22% 4TCr
Weighted average by Cap. +0.13%+2.88%+41.26%+166.97%

Financials

2024 2025
Net sales 53.22L 13.07L 11.78L 10.88L 10L 18.61L 12Cr 19.07L 1.3Cr 51.97L 6.56Cr 49.04L 47.99L 21Cr 56.25L 13.81L 12.45L 11.5L 10.4L 19.67L 13Cr 20.15L 1.38Cr 54.93L 6.94Cr 51.83L 50.73L 22Cr
Net income -72.81L -17.88L -16.11L -14.89L -13.46L -25.46L -17Cr -26.09L -1.78Cr -71.1L -8.98Cr -67.09L -65.66L -29Cr -33.66L -8L -7L -7L -6L -11.77L -7.75Cr -12.06L -82.46L -32.87L -4.15Cr -31.01L -30.35L -13Cr
Net Debt 44.77L 10.99L 10L 9L 8L 15.65L 10Cr 16.04L 1.1Cr 43.72L 5.52Cr 41.25L 40.38L 18Cr 33.94L 8L 8L 7L 6L 11.87L 7.82Cr 12.16L 83.16L 33.15L 4.19Cr 31.27L 30.61L 13Cr
Projected Income Statement - Annual - Supergenics
Logo Supergenics
Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.
Employees
-
  1. Stock Market
  2. Stocks
  3. 03033 Stock